Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGNDGet Rating) by 26.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,146 shares of the biotechnology company’s stock after acquiring an additional 454 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Ligand Pharmaceuticals were worth $331,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. raised its position in Ligand Pharmaceuticals by 58.9% in the third quarter. PNC Financial Services Group Inc. now owns 1,009 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 374 shares in the last quarter. American Century Companies Inc. bought a new stake in Ligand Pharmaceuticals in the third quarter worth about $205,000. TownSquare Capital LLC bought a new stake in Ligand Pharmaceuticals in the third quarter worth about $225,000. Profund Advisors LLC bought a new stake in Ligand Pharmaceuticals in the third quarter worth about $230,000. Finally, Crossmark Global Holdings Inc. raised its position in Ligand Pharmaceuticals by 15.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 1,688 shares of the biotechnology company’s stock worth $261,000 after acquiring an additional 230 shares in the last quarter. Hedge funds and other institutional investors own 97.54% of the company’s stock.

Several equities research analysts have commented on LGND shares. Barclays dropped their price target on shares of Ligand Pharmaceuticals from $185.00 to $165.00 and set an “overweight” rating on the stock in a research report on Friday, February 18th. Benchmark dropped their price target on Ligand Pharmaceuticals from $180.00 to $130.00 and set a “buy” rating on the stock in a research note on Tuesday, February 22nd. StockNews.com initiated coverage on Ligand Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Zacks Investment Research raised Ligand Pharmaceuticals from a “strong sell” rating to a “hold” rating and set a $108.00 price target on the stock in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Ligand Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $180.60.

NASDAQ:LGND opened at $97.27 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 11.15 and a quick ratio of 10.50. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $88.50 and a fifty-two week high of $169.98. The stock’s 50-day moving average is $107.28 and its two-hundred day moving average is $129.66. The stock has a market cap of $1.64 billion, a PE ratio of 29.12, a price-to-earnings-growth ratio of 5.32 and a beta of 1.16.

Ligand Pharmaceuticals (NASDAQ:LGNDGet Rating) last released its earnings results on Thursday, February 17th. The biotechnology company reported $1.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.37. Ligand Pharmaceuticals had a return on equity of 10.29% and a net margin of 20.78%. The company had revenue of $72.47 million for the quarter, compared to analysts’ expectations of $62.70 million. During the same quarter in the previous year, the business posted $1.20 EPS. On average, equities research analysts anticipate that Ligand Pharmaceuticals Incorporated will post 1.32 earnings per share for the current year.

In other Ligand Pharmaceuticals news, Director John W. Kozarich sold 908 shares of Ligand Pharmaceuticals stock in a transaction dated Monday, February 28th. The stock was sold at an average price of $102.62, for a total transaction of $93,178.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 9.70% of the company’s stock.

Ligand Pharmaceuticals Company Profile (Get Rating)

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.

Recommended Stories

Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGNDGet Rating).

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.